Estuary Biotherapeutics

Biotech developing AAV gene therapies for autosomal dominant polycystic kidney disease, with PKD1 and PKD2 programmes.

View on the globe

$103MEquity raised in 2025–20262025 — · 2026 $103M · 2 equity rounds
$103MEquity raised, all time2 equity rounds on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from Oct 2026 to 16 Oct 2026, $103M equity disclosed.Oct 2026: Seed, $10M; 16 Oct 2026: Series A, $93M$1M$3M$10M$30M$100MQ2Q3Q42027Q2Q3Equity round16 Oct 2026 · Series A · $93M · led by RA Capital ManagementOct 2026 · Seed · $10M · led by 4BIO Capital, GVSeries A · $93MSeed · $10M
Funding history: 2 rounds from Oct 2026 to 16 Oct 2026, $103M equity disclosed.Oct 2026: Seed, $10M; 16 Oct 2026: Series A, $93M$1M$3M$10M$30M$100MQ2Q3Q42027Q2Q3Equity round16 Oct 2026 · Series A · $93M · led by RA Capital ManagementOct 2026 · Seed · $10M · led by 4BIO Capital, GV$93M$10M

Funding history 2 rounds · 1 source · newest first

  1. Series A
    Amount$93M
    Post-money—
    ✓ Confirmed
    Lead
    RA Capital Management
    Also
    Biogen New Ventures, Deep Track Capital, National Kidney Foundation Innovation Fund, Pivotal bioVenture Partners, UPMC Enterprises, 4BIO Capital, GV
    Note
    Company launch release (dateline MENLO PARK, Calif., and NEWTON, Mass., October 16, 2026) states the $93M Series A was led by RA Capital Management, which the earlier draft had flagged as unverified. Valuation not disclosed. A family office connected to an individual with ADPKD is also named in the release and not listed. Fierce Biotech (HTTP 403) not read.
    Sources
  2. Seed
    Amount$10M
    Post-money—
    ✓ Confirmed
    Lead
    4BIO Capital, GV
    Note
    $10M seed, co-led by 4BIO Capital and GV, stated in the company launch release (primary). The release does not date the seed separately, so the month of the launch is used. Launch total $103M = $10M seed + $93M Series A.
    Sources

Investors 8

  • 4BIO Capital2
  • GV2
  • RA Capital Management1
  • Biogen New Ventures
  • Deep Track Capital
  • National Kidney Foundation Innovation Fund
  • Pivotal bioVenture Partners
  • UPMC Enterprises

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Menlo Park hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Estuary Biotherapeutics and its logo are trademarks of their owners, used here for identification only.